Navigation Links
Entry inhibitors show promise as drugs with new MOA for treatment of HBV and HDV infection
Date:4/2/2011

Berlin, Germany, Saturday 02 April 2011: Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.1,2

Most current approved therapies directly target viral replication (e.g. nucleotide/side analogues), and can lead to the development of viral resistance or viral rebound after the end of treatment. Entry inhibitors prevent the virus from entering the cell and forming a stable replication complex, limiting the issue of viral rebound and resistance development.

Professor Heiner Wedemeyer, EASL's Secretary General, commented: "The current treatments available for hepatitis B & D are limited. These novel drugs are the first promising treatments for many years. The shift in the mechanism of action of these drugs from inhibiting the virus's replication directly to inhibiting its entry into the cell, and thus its replication means they are less likely to produce viral resistance; a huge problem faced by many of today's clinicians."

One study1 showed that treatment of ex-vivo liver cells with synthetic anti-lipopolysaccharide peptides (SALPs) during and prior to HBV infection was highly effective and dose dependent in inhibiting infection reducing markers of HBV infection (e.g. HBV RNA, HBV antigens) in the concentration range of 4-5 g/mL by 90% and 0.5-2 g/mL by 50%.

The study also demonstrated that SALPs showed activity against other viral (e.g. HIV, herpes) and microbial (e.g. peritonitis, colitis and pneumonia) infections. Therefore, SALPs represent a very promising therapeutic strategy to treat viral hepatitis infection and concomitant bacterial infection which often leads to life threatening systematic complications.

Other studies2,3 illustrated the enormous value of the chimaeric mouse model of chronic HBV and HDV infection for the preclinical evaluation of antiviral drugs. The study demonstrated that the HBV entry inhibitor Myrcludex-B was able to completely block the spread of HBV from cell to cell and to prevent de-novo HDV infection of human hepatocytes.

Professor Wedemeyer commented: "Although there are 35 million people around the world with HDV infection there is currently little to offer them therapeutically. I am therefore delighted to see these new drug developments."


'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-784-306-9451
European Association for the Study of the Liver
Source:Eurekalert

Related biology news :

1. No-entry zones for AIDS virus
2. New growth inhibitors more effective in plants, less toxic to people
3. A powerful new technology to identify HIV inhibitors
4. KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue
5. Will loss of plant diversity compromise Earths life-support systems?
6. New test shows promise for accurate diagnosis of Turner syndrome
7. Stem cells show promise in repairing a childs heart
8. Scripps Research team creates new synthetic compound with HIV-fighting promise
9. RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks
10. Co-management holds promise of sustainable fisheries worldwide
11. New method for making tiny catalysts holds promise for air quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure ... at home or in healthcare facilities during periods of rest. A lightweight, non-invasive ...
Breaking Biology Technology: